Document Detail

Dosing strategies for antiplatelet therapy in percutaneous coronary intervention.
MedLine Citation:
PMID:  20469613     Owner:  NLM     Status:  MEDLINE    
Both clopidogrel and aspirin have been shown to decrease the rate of cardiovascular events and especially stent thrombosis in patients undergoing percutaneous coronary intervention (PCI). However, recent studies have suggested that there is large inter-individual response variability to these drugs (especially to clopidogrel) and that improved inhibition of platelet reactivity using higher doses or new, more potent agents would further reduce the occurrence of cardiovascular events, but may also increase the risk of bleeding. Many different protocols of antiplatelet therapy have been studied and have shown benefit in reducing the rate of major adverse cardiovascular events after PCI. Therefore, the choice of an appropriate antiplatelet therapy protocol is sometimes difficult for the clinician and should be individualized as per the particular patient risk, accounting for both the risk of recurrent cardiovascular events and bleeding. We review the recent data on efficacy and safety of dosing strategies for antiplatelet therapy in PCI.
Gilles Lemesle; Gabriel Maluenda; Laurent Bonello; Cedric Delhaye; Arnaud Sudre; Christophe Bauters; Jean Marc Lablanche
Related Documents :
6239723 - Role of percutaneous transluminal coronary angioplasty in patients with variant angina ...
12665483 - Pilot trial of oral rapamycin for recalcitrant restenosis.
75333 - Post-thyroidectomy thyrotoxicosis.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Hospital practice (1995)     Volume:  38     ISSN:  2154-8331     ISO Abbreviation:  Hosp Pract (1995)     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-05-17     Completed Date:  2010-08-04     Revised Date:  2013-04-10    
Medline Journal Info:
Nlm Unique ID:  101268948     Medline TA:  Hosp Pract (1995)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  50-8     Citation Subset:  AIM; IM    
Pôle de Cardiologie, Hôpital Cardiologique, Service de Cardiologie B et Centre Hémodynamique, Centre Hospitalier Régional et Universitaire de Lille, Lille, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Balloon, Coronary* / adverse effects
Aspirin / administration & dosage*,  adverse effects,  pharmacokinetics
Clinical Protocols
Drug Administration Schedule
Drug Monitoring
Hemorrhage / chemically induced,  prevention & control
Patient Selection*
Platelet Aggregation Inhibitors / administration & dosage*,  adverse effects,  pharmacokinetics
Practice Guidelines as Topic
Purinergic P2 Receptor Antagonists
Risk Assessment
Risk Factors
Thrombosis / etiology,  prevention & control
Ticlopidine / administration & dosage,  adverse effects,  analogs & derivatives*,  pharmacokinetics
Treatment Outcome
Reg. No./Substance:
0/Piperazines; 0/Platelet Aggregation Inhibitors; 0/Purinergic P2 Receptor Antagonists; 0/Thiophenes; 34K66TBT99/prasugrel; 50-78-2/Aspirin; 55142-85-3/Ticlopidine; A74586SNO7/clopidogrel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Approach to non-ST-segment elevation acute coronary syndrome in the emergency department: risk strat...
Next Document:  Intensive insulin therapy in the intensive care unit, hypoglycemia, and cardiovascular mortality.